Radiofrequency Ablation for Treating Liver Metastases from a Non-Colorectal Origin.
10.3348/kjr.2011.12.5.579
- Author:
Bo La YUN
1
;
Jeong Min LEE
;
Ji Hyun BAEK
;
Se Hyung KIM
;
Jae Young LEE
;
Joon Koo HAN
;
Byung Ihn CHOI
Author Information
1. Department of Radiology, Seoul National University Hospital, Seoul 110-744, Korea. jmsh@snu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Liver;
Interventional procedures;
Radiofrequency ablation;
Preliminary clinical study
- MeSH:
Adult;
Aged;
Aged, 80 and over;
*Catheter Ablation/adverse effects;
Disease Progression;
Disease-Free Survival;
Female;
Humans;
Liver Neoplasms/mortality/radiography/*secondary/*surgery;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Radiography, Interventional;
Tomography, X-Ray Computed;
Ultrasonography, Interventional
- From:Korean Journal of Radiology
2011;12(5):579-587
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: We wanted to assess the safety and efficacy of performing radiofrequency ablation (RFA) in patients with non-colorectal liver metastases. MATERIALS AND METHODS: In this retrospective study, 25 patients with 40 hepatic metastases (M:F = 17:8; mean age, 57 years; tumor size, 0.5-5.0 cm) from a non-colorectal origin (stomach, biliary, breast, pancreas, kidney and skin) were treated with RFA. The RFA procedures were performed using either an internally cooled electrode or a clustered electrode under ultrasound or CT guidance. Contrast-enhanced CT scans were obtained immediately after RFA and follow-up CT scans were performed within three months after ablation and subsequently at least every six months. The intrahepatic disease-free interval was estimated and the overall survival from the time of the initial RFA was analyzed using the Kaplan-Meier method. RESULTS: No intraprocedural deaths occurred, but four major complications developed, including abscesses (n = 3) and pneumothorax (n = 1). Technical effectiveness was determined on the initial follow-up images. During the follow-up period (range, 5.9-68.6 months; median time, 18.8 months) for 37 tumors in 22 patients where technical effectiveness was achieved, 12 lesions (32%, 12 of 37) showed local tumor progression and new intrahepatic metastases occurred in 13 patients (59%, 13 of 22). The median intrahepatic disease-free interval was 10.1 months. The 1-year, 3-year and 5-year overall survival rates after RFA were 86%, 39% and 19%, respectively. CONCLUSION: RFA showed intermediate therapeutic effectiveness for the treatment of non-colorectal origin liver metastases.
